company background image
DBV logo

DBV Technologies DB:DBV Stock Report

Last Price

€0.81

Market Cap

€73.5m

7D

27.8%

1Y

-44.6%

Updated

04 Dec, 2024

Data

Company Financials +

DBV Technologies S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DBV Technologies
Historical stock prices
Current Share Price€0.81
52 Week High€1.83
52 Week Low€0.44
Beta0.79
11 Month Change16.40%
3 Month Change6.45%
1 Year Change-44.59%
33 Year Change-84.22%
5 Year Change-94.31%
Change since IPO-90.79%

Recent News & Updates

Recent updates

Shareholder Returns

DBVDE BiotechsDE Market
7D27.8%1.4%3.6%
1Y-44.6%-16.5%9.0%

Return vs Industry: DBV underperformed the German Biotechs industry which returned -16.5% over the past year.

Return vs Market: DBV underperformed the German Market which returned 8.6% over the past year.

Price Volatility

Is DBV's price volatile compared to industry and market?
DBV volatility
DBV Average Weekly Movement14.8%
Biotechs Industry Average Movement6.7%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.7%
10% least volatile stocks in DE Market2.4%

Stable Share Price: DBV's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: DBV's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2002108Daniel Tasséwww.dbv-technologies.com

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.

DBV Technologies S.A. Fundamentals Summary

How do DBV Technologies's earnings and revenue compare to its market cap?
DBV fundamental statistics
Market cap€73.53m
Earnings (TTM)-€97.10m
Revenue (TTM)€11.90m

6.2x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DBV income statement (TTM)
RevenueUS$12.52m
Cost of RevenueUS$0
Gross ProfitUS$12.52m
Other ExpensesUS$114.60m
Earnings-US$102.09m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.06
Gross Margin100.00%
Net Profit Margin-815.73%
Debt/Equity Ratio0%

How did DBV perform over the long term?

See historical performance and comparison